Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neurom
Acceleron Pharma (XLRN) ist ein biopharmazeutische Unternehmen mit vielversprechenden Wachstumschancen. Mit der im November erhaltenen FDA-Zulassung für Reblozyl, einem Mittel für die Behandlung von Anämie (Blutarmut) bei erwachsenen Patienten mit Beta-Thalassämie, war ein Meilenstein. Außerdem gab es positive Daten zur Phase-II-PULSAR-Studie. Sotatercept widmet sich der Behandlung von Patienten...
